Advertisement

Topics

Solasia Pharma K.K. and Camurus AB Company Profile

09:12 EDT 24th September 2018 | BioPortfolio

Solasia was formed in November 2006 by MPM Capital and ITOCHU Corporation to address unmet needs for important new Western oncology therapies and supportive care products throughout Asia. The company’s mission is to expedite patient access to unique oncology therapies through aggressive development and specialized commercialization throughout Japan, China and other Asian countries.


News Articles [556 Associated News Articles listed on BioPortfolio]

China Accepts Solasia's Filing for Anti-Nausea/Vomiting Patch

Tokyo's Solasia Pharma reported China's Center for Drug Evaluation has completed a review of the New Drug Approval filing for Sancuso ®, a granisetron transdermal patch used to treat nausea and vo...

Camurus Announces PDUFA Date for CAM2038 for the Treatment of Opioid use Disorder

LUND, Sweden, 16 July, 2018 /PRNewswire/ -- Camurus (NASDAQ STO: CAMX) announced today that the US Food and Drug Administration (FDA) assigned a Prescription Drug User Fee Act (PDUFA) goal date of...

US FDA assigns PDUFA goal date for Camurus' weekly & monthly buprenorphine depots, CAM2038 to treat opioid use disorder

Camurus, a Swedish research─based pharmaceutical company, announced that the US Food and Drug Administration (FDA) assigned a Prescription Drug User Fee Act (PDUFA) goal date of December 26, 2018 fo...

Solasia Pharma KK 4597 Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 14062018] Prices from USD $250

SummarySolasia Pharma KK Solasia Pharma, formerly JapanBridge Inc is a pharmaceutical company that provides patient access to oncology therapies. The company develops and commercializes oncology thera...

Solasia Pharma KK 4597 Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 11072018] Prices from USD $250

SummarySolasia Pharma KK Solasia Pharma, formerly JapanBridge Inc is a pharmaceutical company that provides patient access to oncology therapies. The company develops and commercializes oncology thera...

Solasia Pharma KK 4597 Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 14032018] Prices from USD $250

SummarySolasia Pharma KK Solasia Pharma formerly JapanBridge Inc is a healthcare service provider that provides patient access to Western oncology therapies. The company develops and commercializes on...

Återlämnar preparat mot jätteväxt

Läkemedelsbolaget Novartis har beslutat att återlämna rättigheterna till läkemedelsprojektet CAM2029 och andra relaterade produktkandidater till Camurus.

Camurus AB CAMX Financial and Strategic SWOT Analysis Review [Report Updated: 09032018] Prices from USD $300

SummaryCamurus AB Camurus, a subsidiary of Sandberg Development AB is a specialty medicine manufacturer that offers drugs for the treatment of chronic diseases. The company offers its products through...

Drugs and Medications [238 Associated Drugs and Medications listed on BioPortfolio]

Fluoride [Libertas Pharma, Inc.]

Fluoride Chewable Tablets 0.5 mg

Fluoride [Libertas Pharma, Inc.]

Fluoride Chewable Tablets 1 mg

Metoprolol tartrate [Med-Health Pharma, LLC]

Metoprolol Tartrate Tablets, USP

Urea [Libertas Pharma, Inc.]

Rx Only 45% Urea Nail Gel In a vehicle containing Camphor, Eucalyptus Oil and Menthol )

Eloxatin [Aventis Pharma Ltd.]

PubMed Articles [22 Associated PubMed Articles listed on BioPortfolio]

Data and Corporate Governance in Pharma and Digital Health: A Necessary Regulatory Convergence.

Data and Corporate Governance in Pharma and Digital Health: A Necessary Regulatory Convergence.

Clinical trials go virtual, big pharma dives in.

21 Century Citizen Pharma: The FDA & Patient-Focused Product Development.

Perpetual debate regarding the delicate balance between access and innovation and the protection of the public health and safety dominate discussions of the United States Food and Drug Administration ...

A guide to manufacturing CAR T cell therapies.

In recent years, chimeric antigen receptor (CAR) modified T cells have been used as a treatment for haematological malignancies in several phase I and II trials and with Kymriah of Novartis and Yescar...

The Common Pharmaceutical Market of the Eurasian Economic Union: A Regulatory Review.

According to the Treaty on the Eurasian Economic Union, a common pharmaceutical market was supposed to become operational on January 1, 2016. Nevertheless, the responsible parties did not meet the dea...

Clinical Trials [83 Associated Clinical Trials listed on BioPortfolio]

Rivastigmine Bioequivalence Trial With Multiple Application of Transdermal Patches (9.5mg/24h)

The present clinical trial will be conducted in order to compare the bioavailability of rivastigmine and to assess bioequivalence at steady-state of the Test product RID-TDS 9.5 mg/24 h (L...

To Demonstrate the Relative Bioavailability of Sandoz Inc. and UCB Pharma, Inc (Keppra) 750 mg Levetiracetam Tablets In Healthy Adults Volunteers Under Fasting Conditions

To demonstrate the relative bioavailability of Sandoz Inc. and UCB Pharma, Inc (Keppra) 750 mg Levetiracetam tablets in healthy adult volunteers under fasting conditions.

Pharma-Pen (Formerly Innoject) Auto-Injectory TIV

The purpose of this study is to evaluate the safety, effectiveness, and tolerability, of the Pharma-Pen(TM) intramuscular (IM) and subcutaneous (SC) auto-injector systems used by untrained...

A Bioequivalence Study of Cefadroxil From Duricef 1 gm F.C.T (GSK) and Biodroxil 1 gm F.C.T (Novartis Pharma)

Comparative randomized, single dose, two-way crossover open-label study to determine the bioequivalence of Cefadroxil from Duricef 1 gm Film Coated tablets(Smthkline Beecham Egypt,LLC aff...

Steady State Global Bioequivalence Study of Amphotericin B Liposome for Injection 50 mg/ Vial in Fed Condition

The primary objective is to determine clinical bioequivalence of Amphotericin B liposome for injection of Auromedics Pharma LLC, USA and AmBisome (Amphotericin B) liposome for injection of...

Companies [765 Associated Companies listed on BioPortfolio]

Solasia Pharma K.K. and Camurus AB

Solasia was formed in November 2006 by MPM Capital and ITOCHU Corporation to address unmet needs for important new Western oncology therapies and supportive care products througho...

Solasia Pharma K.K.

Solasia Pharma K.K. (Tokyo, Japan) was formed in November 2006 by MPM Capital and Itochu Corporation to address unmet needs for important new Western oncology therapies throughout...

Camurus AB

Camurus is a drug delivery company, within the healthcare sector, that specializes in formulation technologies of sparingly water soluble drug substances. Camurus offer proprietary technology platform...

H3 Pharma Incorporated

H3 Pharma Inc. is a Venture Pharma focusing on the development of human therapeutic products oriented towards age-related disorders. At H3 Pharma, we aim to be the best at identifying, evaluating and ...

LEO Pharma Inc.

LEO Pharma Inc. is headquartered in Parsippany, New Jersey, and is the U.S. affiliate of Denmark-based LEO Pharma A/S, a global leader in dermatology and critical care with more t...

More Information about "Solasia Pharma K.K. and Camurus AB" on BioPortfolio

We have published hundreds of Solasia Pharma K.K. and Camurus AB news stories on BioPortfolio along with dozens of Solasia Pharma K.K. and Camurus AB Clinical Trials and PubMed Articles about Solasia Pharma K.K. and Camurus AB for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Solasia Pharma K.K. and Camurus AB Companies in our database. You can also find out about relevant Solasia Pharma K.K. and Camurus AB Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...


Corporate Database Quicklinks



Searches Linking to this Company Record